ATTR-CM: Transthyretin amyloid cardiomyopathy; TTR: Transthyretin.
References:
- Narotsky DL, Castano A, Weinsaft JW, Bokhari S, Maurer MS. Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging. Can J Cardiol. 2016;32(9):1166.e1-1166.e10.
- Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy: Update in the diagnosis and treatment of the most common types. Curr Opin Cardiol. 2018;33(5):571-579.
- Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016;23(4):209-213.
- Siddiqi OK, Ruberg FL. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018;28(1):10-21.
- Halwani O, Delgado DH. Cardiac amyloidosis: An approach to diagnosis and management. Expert Rev Cardiovasc Ther. 2010;8(7):1007-1013.
- Rapezzi C, Lorenzini M, Longhi S, et al. Cardiac amyloidosis: The great pretender. Heart Fail Rev. 2015;20(2):117-124.
- Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017;135(14):1357-1377.
- Castaño A, et al. J Am Coll Cardiol. 2015. Available at: https://www.acc.org/latest-in-cardiology/articles/2015/10/13/08/35/emerging-therapies-for-transthyretin-cardiac-amyloidosis. Accessed January 12, 2022.
- Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012;109(24):9629-9634.
- Hammarström P, Jiang X, Hurshman AR, Powers ET, Kelly JW. Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc Natl Acad Sci U S A. 2002;99(suppl 4):16427-16432.
